文献速递临床试验与 GCP

混合胸腔镜手术与经静脉导管消融对比经静脉导管消融治疗持续性和长程持续性心房颤动(HARTCAP-AF):随机试验研究方案

Hybrid thoracoscopic surgical and transvenous catheter ablation versus transvenous catheter ablation in persistent and longstanding persistent atrial fibrillation (HARTCAP-AF): study protocol for a randomized trial.
PubMed 文献 · Trials · 2019-06-20

HARTCAP-AF试验为随机对照试验,纳入40例持续性或长程持续性心房颤动患者,1:1随机分配至混合消融组或(重复)导管消融组。主要有效性终点为末次术后12个月内无任何持续超过5分钟的室上性心律失常且未使用Vaughan-Williams I类或III类抗心律失常药物。导管消融组允许在索引术后6个月内计划第二次手术以达成主要终点。

要点

  • 混合消融对比(重复)导管消融治疗持续性及长程持续性心房颤动,假设混合消融更有效且不增加主要不良事件。
  • 主要有效性终点为末次术后12个月无持续超过5分钟的室上性心律失常且未用I/III类抗心律失常药。
  • 导管消融组允许索引术后6个月内计划第二次手术以获取主要终点。

核心结论

  • HARTCAP-AF试验假设混合心房颤动消融在(长程)持续性心房颤动中比(重复)经静脉心内膜导管消融更有效,且不增加相关主要不良事件数量。

研究设计与样本

  • 随机对照试验,纳入40例持续性或长程持续性心房颤动患者,1:1随机分配至混合消融组或(重复)导管消融组。
  • 手术和随访按指南进行。

主要发现

  • 主要有效性终点为末次手术后12个月随访期间无任何持续超过5分钟的室上性心律失常且未使用Vaughan-Williams I类或III类抗心律失常药物。
  • 导管消融组允许在索引术后6个月内计划第二次手术以获取主要终点。
  • 将记录不良事件、成本效果和生活质量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Success rates with conventional transvenous endocardial pulmonary vein isolation in patients with persistent and longstanding persistent atrial fibrillation (AF) are variable due to advanced electrical and structural remodeling of the atria. As a consequence, more extensive endocardial lesions, minimally invasive thoracoscopic surgical techniques, and hybrid ablation (combining thoracoscopic epicardial surgical and endocardial catheter ablation) have been developed. HYPOTHESIS: The HARTCAP-AF trial hypothesizes that hybrid AF ablation is more effective than (repeated) transvenous endocardial catheter ablation in (longstanding) persistent AF, without increasing the number of associated major adverse events. METHODS: This randomized controlled trial will include 40 patients with persistent or longstanding persistent AF who will be 1:1 randomized to either hybrid ablation or (repeated) catheter ablation. The procedures and follow-up are conducted according to the guidelines. The primary effectiveness endpoint is freedom from any supraventricular arrhythmia lasting longer than 5 min without the use of Vaughan-Williams class I or III antiarrhythmic drugs through 12 months of follow-up after the last procedure. In the catheter ablation arm, a second procedure planned within 6 months after the index procedure is allowed for obtaining the primary endpoint. Additionally, adverse events, cost-effectiveness, and quality of life data will be recorded. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02441738 . Registered on 12 May 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Vroomen M, La Meir M, Maesen B, et al. Hybrid thoracoscopic surgical and transvenous catheter ablation versus transvenous catheter ablation in persistent and longstanding persistent atrial fibrillation (HARTCAP-AF): study protocol for a randomized trial. Trials. 2019. PMID: 31221218. doi:10.1186/s13063-019-3365-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。